| Androgen receptor function and androgen receptor–targeted therapies in breast cancer: a review M Kono, T Fujii, B Lim, MS Karuturi, D Tripathy, NT Ueno JAMA oncology 3 (9), 1266-1273, 2017 | 218 | 2017 |
| Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience T Fujii, RR Colen, MA Bilen, KR Hess, J Hajjar, ME Suarez-Almazor, ... Investigational new drugs 36, 638-646, 2018 | 164 | 2018 |
| Targeting isocitrate dehydrogenase (IDH) in cancer T Fujii, MR Khawaja, CD DiNardo, JT Atkins, F Janku Discovery medicine 21 (117), 373-380, 2016 | 163 | 2016 |
| Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer T Fujii, T Kogawa, W Dong, AA Sahin, S Moulder, JK Litton, D Tripathy, ... Annals of Oncology 28 (10), 2420-2428, 2017 | 151 | 2017 |
| Radiomics to predict immunotherapy-induced pneumonitis: proof of concept RR Colen, T Fujii, MA Bilen, A Kotrotsou, S Abrol, KR Hess, J Hajjar, ... Investigational new drugs 36, 601-607, 2018 | 108 | 2018 |
| Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: a systematic review and network meta-analysis T Fujii, F Le Du, L Xiao, T Kogawa, CH Barcenas, RH Alvarez, V Valero, ... JAMA oncology 1 (9), 1311-1318, 2015 | 90 | 2015 |
| Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis N Yamaguchi, T Fujii, S Aoi, PS Kozuch, GN Hortobagyi, RH Blum European Journal of Cancer 51 (16), 2314-2320, 2015 | 84 | 2015 |
| Biomarkers of response to immune checkpoint blockade in cancer treatment T Fujii, A Naing, C Rolfo, J Hajjar Critical reviews in oncology/hematology 130, 108-120, 2018 | 78 | 2018 |
| Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers T Fujii, A Barzi, A Sartore-Bianchi, A Cassingena, G Siravegna, DD Karp, ... Clinical Cancer Research 23 (14), 3657-3666, 2017 | 66 | 2017 |
| MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction F Janku, HJ Huang, T Fujii, DN Shelton, K Madwani, S Fu, ... Annals of Oncology 28 (3), 642-650, 2017 | 46 | 2017 |
| Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression ME Reyes, T Fujii, D Branstetter, S Krishnamurthy, H Masuda, X Wang, ... Breast cancer research and treatment 164, 57-67, 2017 | 40 | 2017 |
| EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients … F Le Du, T Fujii, K Kida, DW Davis, M Park, DD Liu, W Wu, ... PLoS One 15 (3), e0229903, 2020 | 31 | 2020 |
| Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer NT Ueno, RK Tahara, T Fujii, JM Reuben, H Gao, B Saigal, A Lucci, ... Cancer medicine 9 (3), 1025-1032, 2020 | 29 | 2020 |
| Differential impact of fosaprepitant on infusion site adverse events between cisplatin-and anthracycline-based chemotherapy regimens T Fujii, N Nishimura, KY Urayama, H Kanai, H Ishimaru, J Kawano, ... Anticancer Research 35 (1), 379-383, 2015 | 29 | 2015 |
| High HER2/centromeric probe for chromosome 17 fluorescence in situ hybridization ratio predicts pathologic complete response and survival outcome in patients receiving … T Kogawa, TM Fouad, DD Liu, J Wu, Y Shen, H Masuda, T Fujii, ... The oncologist 21 (1), 21-27, 2016 | 25 | 2016 |
| Association of body mass index changes during neoadjuvant chemotherapy with pathologic complete response and clinical outcomes in patients with locally advanced breast cancer T Kogawa, TM Fouad, C Wei, H Masuda, K Kai, T Fujii, R El-Zein, ... Journal of Cancer 6 (4), 310, 2015 | 25 | 2015 |
| Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy T Fujii, T Kogawa, J Wu, AA Sahin, DD Liu, M Chavez-MacGregor, ... British journal of cancer 116 (4), 509-514, 2017 | 24 | 2017 |
| Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis M Kono, T Fujii, N Matsuda, K Harano, H Chen, C Wathoo, AY Joon, ... Journal of Cancer 9 (19), 3640, 2018 | 23 | 2018 |
| Androgen receptor expression on circulating tumor cells in metastatic breast cancer T Fujii, JM Reuben, L Huo, JR Espinosa Fernandez, Y Gong, R Krupa, ... PLoS One 12 (9), e0185231, 2017 | 23 | 2017 |
| The efficacy of nonestrogenic therapy to hot flashes in cancer patients under hormone manipulation therapy: a systematic review and meta-analysis N Yamaguchi, Y Okajima, T Fujii, A Natori, D Kobayashi Journal of cancer research and clinical oncology 139, 1701-1707, 2013 | 19 | 2013 |
